Patient and treatment factors associated with survival among pediatric glioblastoma patients: A Surveillance, Epidemiology, and End Results study

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
Sandi LamI-Wen Pan

Abstract

Glioblastoma (GBM) is a rare malignancy in children. The United States Surveillance, Epidemiology, and End Results (SEER) database allows large-scale analyses of clinical characteristics and prognostic features. We used it to study patients aged <20 years with histologically confirmed GBM (2000-2010) and examined the relationship between patient demographics, tumor characteristics, patterns of treatment, and outcomes. The primary outcome was disease-specific survival. 302 subjects were identified, with median age 11 years. Median follow-up was 32 months (95% CI 27-39). 34.4% had gross total resection (GTR). 61% underwent radiation after surgery (17% of subjects <3 years, 67% of those aged 4-19 years). Median survival and 2-year survival rates were 20 months and 46.9%, respectively. In multivariate analyses, age, tumor location, extent of resection, and year of diagnosis were significantly associated with the primary outcome. Compared to those aged 0-4 years, subjects aged 5-9 years and 10-14 years had higher risk of mortality. Infratentorial tumor location (HR 2.0, 95% CI 1.2-3.3, p = 0.007) and subtotal resection (HR 2.04, 95% CI 1.4-3.0, p < 0.001) were associated with increased mortality. Later year of diagnosis was signific...Continue Reading

Citations

Dec 14, 2019·Cancer Metastasis Reviews·Patricia KattnerKlaus-Michael Debatin
Jan 25, 2021·Advanced Drug Delivery Reviews·Taskeen Iqbal JanjuaAmirali Popat
Jan 21, 2021·Brain Sciences·Donata SimińskaIrena Baranowska-Bosiacka
May 1, 2021·Cancers·Aleksandra NapieralskaMaciej Harat
Dec 12, 2020·Journal of Neurosurgery. Pediatrics·Marcos Devanir Silva da CostaSergio Cavalheiro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.